Skip to main content

Table 1 Patient demographics and clinical charateristics

From: HPV E6/E7 mRNA in situ hybridization in endocervical adenocarcinoma: implications for prognosis and diagnosis

Characteristic Total (n = 200) HPVA (n = 185) NHPVA (n = 15) Pa
No. (%) No. (%) No. (%)
Age     0.014
 ≤ 37 34 (17.0%) 28 (82.4%) 6 (17.6%)  
 > 37 166 (83.0%) 157 (94.6%) 9 (5.4%)  
HPV DNA      < 0.001
 Negative (0–1 pg/ml) 34 (17.0%) 26 (76.5%) 8 (23.5%)  
 Positive (≥ 1 pg/ml) 110 (55.0%) 108 (98.2%) 2 (1.8%)  
 Not avaiable 56 (28.0%) 51 (51.8%) 5 (4.2%)  
HPV genotype     0.273
 HPV 16 49 (24.5%) 47 (95.9%) 2 (4.1%)  
 HPV 18 60 (30.0%) 57 (95.5%) 3 (5.0%)  
 Other 11 (5.5%) 11 (100.0%) 0 (0.0%)  
 Negative 72 (36.0%) 63 (87.5%) 9 (12.5%)  
 Not avaiable 8 (4%) 7 (87.5%) 1 (12.5%)  
HPV RNAscope     0.003
 ≤ 3.3 99 (49.5%) 86 (46.5%) 13 (13.1%)  
 > 3.3 101 (50.5%) 99 (98.0%) 2 (2.0%)  
Tumor size (cm)     0.004
 ≤ 4.5 178 (89.0%) 168 (94.4%) 10 (5.6%)  
 > 4.5 22 (11.0%) 17 (77.3%) 5 (22.7%)  
FIGO stage      < 0.001
 I 141 (70.5%) 137 (97.2%) 4 (2.8%)  
 II 51 (25.5%) 43 (84.3%) 8 (15.7%)  
 III 5 (2.5%) 4 (80.0%) 1 (20.0%)  
 IV 3 (1.5%) 1 (33.3%) 2 (66.7%)  
Differentiation     0.537
 Good 10 (5.0%) 7 (70.0%) 3 (30.0%)  
 Moderate 106 (53.0%) 96 (90.6%) 10 (9.4%)  
 Poor 84 (42.0%) 82 (97.6%) 2 (2.4%)  
LVI     0.141
 None (0) 138 (69.0%) 130 (94.2%) 8 (5.8%)  
 Focal (1–4) 37 (18.5%) 31 (83.8%) 6 (16.2%)  
 Moderate (5–9) 15 (7.5%) 14 (93.3%) 1 (6.7%)  
 Extensive (≥ 10) 10 (66.7%) 10 (100.0%) 0 (0.0%)  
Invasion level of uterine cervix     0.008
 < 1/3 54 (27.0%) 53 (98.1%) 1 (1.9%)  
 1/3–2/3 61 (31.0%) 60 (96.8%) 2 (3.2%)  
 ≥ 2/3 84 (42.0%) 72 (85.7%) 12 (14.3%)  
Lymph nodes invasion     0.024
 No 154 (77.0%) 146 (94.8%) 8 (5.2%)  
 Yes 46 (23.0%) 39 (84.8%) 7 (46.7%)  
Parametrium invasion     0.599
 No 181 (90.5%) 168 (92.8%) 13 (7.2%)  
 Yes 19 (9.5%) 17 (89.5%) 2 (10.5%)  
Surgical margin      < 0.001
 No 187 (93.5%) 177 (94.7%) 10 (5.3%)  
 Yes 13 (6.5%) 8 (61.5%) 5 (38.5%)  
Treatment     0.235
 Surgery 83 (41.5%) 80 (96.4%) 3 (3.6%)  
 Surgery + chemotherapy 21 (10.5%) 20 (95.2%) 1 (4.8%)  
 Surgery + radiotherapy 41 (20.5%) 36 (87.8%) 5 (12.2%)  
 Surgery + chemoradiation 55 (27.5%) 49 (89.1%) 6 (10.9%)  
MMR status     0.978
 dMMR 13 (6.5%) 12 (92.3%) 1 (7.7%)  
 pMMR 187 (93.5%) 173 (92.5%) 14 (7.5%)  
P16 IHC     0.001
 Negative 82 (41.0%) 70 (85.4%) 12 (14.6%)  
 Positive 118 (59.0%) 115 (97.5%) 3 (2.5%)  
Ki-67 IHC     0.131
 ≤ 12.5% 48 (24%) 42 (87.5%) 6 (12.5%)  
 > 12.5% 152 (76%) 143 (94.1%) 9 (5.9%)  
  1. aChi-square test. HPVA, HPV-associated adenocarcinoma; NHPVA, nonHPV-associated adenocarcinoma; IHC, immunohistochemistry; LVI, lymph vascular invasion; dMMR, delete mismatch repair; pMMR, proficient mismatch repair